SCHEDULE 13G/A: FMR LLC and Abigail Johnson Disclose 15% Stake in Scholar Rock Holding Corp
Beneficial Ownership Update
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a beneficial ownership of 15.0% of Scholar Rock Holding Corp.'s common stock as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson, as reporting persons, beneficially own an aggregate of 14,114,029 shares of Scholar Rock Holding Corp. common stock.
- This ownership represents 15.0% of the total outstanding common stock of Scholar Rock Holding Corp.
- The filing is an Amendment No. 8 to Schedule 13G, indicating an update to their previously reported ownership position.
- The beneficial ownership was calculated as of December 31, 2024.
- FMR LLC holds sole voting power over 14,112,783 shares and sole dispositive power over 14,114,029 shares.
- Abigail P. Johnson holds sole dispositive power over 14,114,029 shares, with no sole or shared voting power directly.
- Fidelity Growth Company Commingled Pool, an entity associated with FMR LLC, is known to have an interest in 4,903,393 shares, representing 5.2% of the total outstanding common stock as of December 31, 2024.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The continued significant beneficial ownership by FMR LLC and Abigail P. Johnson in Scholar Rock Holding Corp. suggests ongoing institutional confidence in the company. This is a routine disclosure of a substantial, non-activist stake.
Positives
- A major institutional investor, FMR LLC (Fidelity), and its top executive, Abigail P. Johnson, maintaining a significant 15.0% stake in Scholar Rock Holding Corp. indicates continued confidence in the company.
- The substantial holding by Fidelity Growth Company Commingled Pool (5.2%) further underscores institutional interest in Scholar Rock Holding Corp.
Risks
- The document is a beneficial ownership disclosure and does not detail specific operational or financial risks related to Scholar Rock Holding Corp.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11." (Certification by FMR LLC and Abigail P. Johnson via Stephanie J. Brown)
Industry Context
This filing is a standard disclosure of a significant ownership stake by a major asset management firm in a biotechnology company. It does not provide specific industry trends or competitive analysis, but the continued substantial investment by FMR LLC in Scholar Rock Holding Corp. suggests ongoing institutional interest in the biotechnology sector, particularly in companies like Scholar Rock.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence investor perception and potentially stock liquidity.
- Management: Awareness of a large, stable institutional holder can influence strategic decisions, though the filing explicitly states the stake is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2024-12-31 | Date of event which requires filing of this statement; beneficial ownership calculated as of this date. |
| 2025-02-11 | Date of signing and filing of the Schedule 13G Amendment No. 8. |
Keywords
Scholar Rock Holding Corp, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SRRK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.